MLN2222

MLN2222 is a potent and selective inhibitor of the complement system, specifically designed to block complement activation. It was developed as a therapeutic agent to prevent or mitigate acute toxicities associated with rapid infusion of phosphorothioate oligonucleotides and other conditions where complement activation plays a pathogenic role. The drug acts by inhibiting the alternative pathway of the complement cascade, thereby preventing downstream effects such as inflammation and tissue damage. MLN2222 was initially developed by Millennium Pharmaceuticals (now part of Takeda Pharmaceutical) for indications including coronary artery disease but its development has been discontinued[1][9]. Some sources also describe it as a caspase inhibitor; however, primary literature supports its main mechanism as a complement inhibitor[1][2].

Other names

complement activation blocker-2CAB-2CAB2CAB 2